Free Trial

Tharimmune (THAR) Competitors

Tharimmune logo
$1.76 0.00 (-0.23%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

THAR vs. BIVI, RVPH, CING, JATT, MTEX, QTTB, MRKR, LPCN, CARM, and PRPH

Should you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include BioVie (BIVI), Reviva Pharmaceuticals (RVPH), Cingulate (CING), JATT Acquisition (JATT), Mannatech (MTEX), Q32 Bio (QTTB), Marker Therapeutics (MRKR), Lipocine (LPCN), Carisma Therapeutics (CARM), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry.

Tharimmune vs. Its Competitors

BioVie (NASDAQ:BIVI) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

BioVie has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

BioVie's return on equity of -100.88% beat Tharimmune's return on equity.

Company Net Margins Return on Equity Return on Assets
BioVieN/A -100.88% -78.49%
Tharimmune N/A -489.33%-264.34%

4.6% of BioVie shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 2.4% of BioVie shares are owned by company insiders. Comparatively, 10.0% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, BioVie had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Tharimmune. BioVie's average media sentiment score of 0.86 beat Tharimmune's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company Overall Sentiment
BioVie Positive
Tharimmune Neutral

Tharimmune is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/A-$32.12M-$79.10-0.10
TharimmuneN/AN/A-$12.20M-$7.88-0.23

Tharimmune has a consensus target price of $17.00, suggesting a potential upside of 857.75%. Given Tharimmune's higher probable upside, analysts plainly believe Tharimmune is more favorable than BioVie.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioVie
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Tharimmune
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

Summary

BioVie beats Tharimmune on 7 of the 13 factors compared between the two stocks.

Get Tharimmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

THAR vs. The Competition

MetricTharimmuneMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.72M$2.96B$5.57B$9.02B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-0.2321.1627.2120.15
Price / SalesN/A260.59416.26185.35
Price / CashN/A41.8337.0657.97
Price / Book2.617.768.085.60
Net Income-$12.20M-$54.96M$3.16B$248.50M
7 Day Performance-3.32%5.99%3.74%5.11%
1 Month Performance11.29%4.41%3.88%7.58%
1 Year Performance-51.50%6.36%34.26%21.53%

Tharimmune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
THAR
Tharimmune
2.9397 of 5 stars
$1.78
+0.9%
$17.00
+857.7%
-49.9%$4.72MN/A-0.232
BIVI
BioVie
0.8652 of 5 stars
$0.99
+5.8%
N/A+96.3%$18.29MN/A-0.1210News Coverage
RVPH
Reviva Pharmaceuticals
2.4579 of 5 stars
$0.38
+2.9%
$9.00
+2,268.4%
-67.5%$18.24MN/A-0.485Gap Up
CING
Cingulate
2.7282 of 5 stars
$4.27
+3.1%
$26.00
+508.9%
+1,116.8%$18.15MN/A-0.5020News Coverage
JATT
JATT Acquisition
N/A$1.05
flat
N/A-66.7%$18.11MN/A0.003High Trading Volume
MTEX
Mannatech
0.2962 of 5 stars
$9.45
+2.9%
N/A+18.8%$17.96M$117.87M-94.50250
QTTB
Q32 Bio
2.0572 of 5 stars
$1.46
+1.7%
$12.17
+731.1%
-92.6%$17.81M$1.16M-0.3039Gap Up
MRKR
Marker Therapeutics
3.69 of 5 stars
$1.57
+4.0%
$13.17
+738.6%
-63.4%$17.76M$6.59M-1.1860
LPCN
Lipocine
1.5854 of 5 stars
$3.21
+0.5%
$9.00
+180.8%
-58.4%$17.15M$11.20M-3.1410
CARM
Carisma Therapeutics
2.4126 of 5 stars
$0.41
+0.5%
$1.93
+373.0%
-64.8%$17.05M$19.63M-0.2620Gap Down
PRPH
ProPhase Labs
N/A$0.40
+5.0%
N/A-87.9%$16.66M$6.77M-0.32130Gap Up

Related Companies and Tools


This page (NASDAQ:THAR) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners